STRATA Skin Sciences, Inc. (SSKN) Key Metrics
SSKN valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $1,177
- Enterprise value
- $8.4M
- P/E (TTM)
- —
- Forward P/E
- 188.7
- PEG ratio
- 0.03
- Price / sales
- —
- Price / book
- 0.0
- EV / EBITDA
- 47.4
- Dividend yield
- —
- Beta
- 0.21
SSKN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSSKN returns How much profit the business earns on the capital it uses.
SSKN financial health Debt, liquidity and how easily interest is covered.
SSKN efficiency & capital use Working capital cycle and where the cash goes.
SSKN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SSKN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SSKN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Per share | ||||||||||
| Revenue per share | — | — | — | — | — | — | — | — | $4.77 | $13.71 |
| Earnings per share | — | — | — | — | — | — | — | — | −$3.26 | −$1.44 |
| Operating cash flow per share | — | — | — | — | — | — | — | — | $0.63 | $0.14 |
| Free cash flow per share | — | — | — | — | — | — | — | — | $0.36 | −$0.30 |
| Cash per share | — | — | — | — | — | — | — | — | $0.62 | $1.70 |
| Book value per share | — | — | — | — | — | — | — | — | $3.37 | $6.36 |
| Tangible book value per share | — | — | — | — | — | — | — | — | $0.32 | −$3.24 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | $0.00 |
| Capex per share | — | — | — | — | — | — | — | — | $0.26 | $0.44 |
| Debt per share | — | — | — | — | — | — | — | — | $1.61 | $10.29 |
| Shares outstanding | — | — | — | — | — | — | — | — | 6.6M | 2.3M |
| Change in shares outstanding | — | — | — | — | — | — | — | — | +185.0% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −158.9% | −114.2% | −62.7% | −23.5% | −10.5% | −16.2% | −12.7% | −15.1% | −116.4% | −21.7% |
| Return on invested capital (ROIC) | −36.3% | −41.0% | −29.3% | −16.1% | −14.8% | −11.6% | −9.3% | −10.4% | −6.0% | −8.3% |
| Return on assets (ROA) | −18.8% | −25.8% | −23.0% | −11.2% | −5.8% | −9.4% | −8.0% | −9.4% | −52.6% | −7.1% |
| Return on tangible assets | −24.3% | −35.8% | −38.4% | −21.3% | −9.8% | −13.9% | −12.4% | −13.9% | −116.3% | −15.9% |
| Free cash flow margin | −13.9% | −4.3% | −16.6% | −12.9% | −7.2% | −0.3% | −1.8% | 3.8% | 7.6% | −2.2% |
| Financial health | ||||||||||
| Total debt | $16.3M | $16.4M | $15.6M | $8.4M | $8.0M | $10.9M | $8.7M | $7.4M | $10.6M | $23.8M |
| Cash & short-term investments | $7.9M | $7.3M | $6.8M | $5.4M | $12.6M | $10.6M | $8.1M | $16.5M | $4.1M | $3.9M |
| Net debt | $8.4M | $9.2M | $8.8M | $3.0M | −$4.6M | $278,000 | $537,000 | −$9.1M | $6.5M | $19.9M |
| Debt / equity | 5.59 | 3.31 | 1.23 | 0.39 | 0.32 | 0.42 | 0.30 | 0.24 | 0.48 | 1.62 |
| Debt / assets | 0.53 | 0.45 | 0.37 | 0.16 | 0.17 | 0.23 | 0.18 | 0.16 | 0.27 | 0.55 |
| Net debt / EBITDA | 47.21 | — | — | 2.67 | −2.64 | — | 0.30 | −4.45 | 1.44 | 7.19 |
| Current ratio | 0.58 | 1.13 | 1.28 | 1.30 | 1.56 | 1.32 | 1.35 | 2.69 | 1.40 | 1.75 |
| Quick ratio | 0.48 | 0.98 | 1.06 | 0.89 | 1.29 | 1.14 | 1.18 | 2.37 | 1.01 | 1.29 |
| Interest coverage | -3.0 | -4.4 | -5.2 | -5.0 | -14.0 | -19.3 | -5.8 | — | -0.8 | -0.7 |
| Working capital | −$11.1M | $2.0M | $3.4M | $4.1M | $7.2M | $6.0M | $6.1M | $14.6M | $3.1M | $4.6M |
| Invested capital | $11.3M | $14.2M | $21.5M | $24.8M | $20.9M | $26.2M | $29.2M | $22.2M | $28.8M | $34.6M |
| Tangible asset value | −$1.9M | −$3.0M | −$1.1M | −$4.4M | $6.5M | $10.7M | $11.9M | $12.7M | $2.1M | −$7.5M |
| Net current asset value | −$12.0M | −$14.6M | −$13.8M | −$12.9M | −$1.2M | $3.9M | $4.9M | $7.0M | −$5.6M | −$17.7M |
| Graham net-net per share | — | — | — | — | — | — | — | — | −$1.28 | −$8.89 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | — | — | $0 | — | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | 0.0% | 0.0% | — |
| Capex / revenue | 4.8% | 4.9% | 15.0% | 9.8% | 12.2% | 9.4% | 8.8% | 5.9% | 5.5% | 3.2% |
| Capex / operating cash flow | — | 870.2% | — | — | 242.2% | 103.0% | 125.2% | 60.8% | 42.0% | 313.0% |
| Capex / depreciation | 0.33 | 0.31 | 0.85 | 0.62 | 0.89 | 0.55 | 0.58 | 0.33 | 0.27 | 0.16 |
| Stock-based compensation / revenue | 2.1% | 1.3% | 3.9% | 4.1% | 5.5% | 7.1% | 3.8% | — | 0.6% | 0.4% |
| R&D / revenue | 1.4% | 2.6% | 3.9% | 2.8% | 4.8% | 5.5% | 3.2% | 3.6% | 5.4% | 6.1% |
| SG&A / revenue | 75.9% | 70.3% | 70.3% | 70.2% | 76.1% | 73.3% | 70.5% | 65.0% | 59.3% | 65.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 55.7 | 52.7 | 48.8 | 39.9 | 38.8 | 57.9 | 44.9 | 39.9 | 37.9 | 42.9 |
| Days of inventory on hand | 72.1 | 62.0 | 100.7 | 114.6 | 124.9 | 131.9 | 93.9 | 83.2 | 78.8 | 100.3 |
| Days payables outstanding | 73.9 | 72.8 | 82.9 | 79.2 | 100.7 | 94.6 | 131.3 | 122.4 | 55.8 | 91.0 |
| Cash conversion cycle (days) | 53.9 | 41.9 | 66.5 | 75.3 | 63.1 | 95.2 | 7.5 | 0.7 | 60.8 | 52.2 |
| Receivables turnover | 6.55 | 6.92 | 7.49 | 9.15 | 9.40 | 6.30 | 8.12 | 9.14 | 9.63 | 8.52 |
| Payables turnover | 4.94 | 5.01 | 4.40 | 4.61 | 3.63 | 3.86 | 2.78 | 2.98 | 6.54 | 4.01 |
| Inventory turnover | 5.07 | 5.89 | 3.62 | 3.19 | 2.92 | 2.77 | 3.89 | 4.39 | 4.63 | 3.64 |
| Asset turnover | 0.92 | 0.86 | 0.71 | 0.73 | 0.64 | 0.49 | 0.67 | 0.69 | 0.77 | 0.67 |
| Average receivables | $4.7M | $4.8M | $4.5M | $4.0M | $3.2M | $3.7M | $3.9M | $3.3M | $3.3M | $3.7M |
| Average payables | $2.6M | $2.9M | $3.4M | $3.1M | $2.8M | $2.3M | $4.1M | $4.3M | $2.1M | $3.1M |
| Average inventory | $2.5M | $2.5M | $4.1M | $4.5M | $3.5M | $3.2M | $2.9M | $2.9M | $2.9M | $3.5M |
| Intangibles / total assets | 15.7% | 22.1% | 32.9% | 50.1% | 40.5% | 32.4% | 35.4% | 39.1% | 52.1% | 51.4% |
Computed from SSKN's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SSKN valuation and financial ratios
STRATA Skin Sciences earned a return on equity of −158.9% and a return on invested capital of −36.3% in fiscal 2025. It ended the year with $16.3 million of debt and $7.9 million in cash and short-term investments, net debt of $8.4 million.
See the SSKN income statement, the SSKN chart for price history, or the SSKN stock overview for the latest quote and news.
SSKN key metrics FAQ
What is STRATA Skin Sciences's return on equity?
STRATA Skin Sciences's return on equity (ROE) was −158.9% in fiscal 2025: net income of -$6.3 million on average shareholders' equity of $3.9 million.
What is STRATA Skin Sciences's ROIC?
STRATA Skin Sciences's return on invested capital was −36.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does STRATA Skin Sciences have?
STRATA Skin Sciences had total debt of $16.3 million at the end of fiscal 2025, a debt-to-equity ratio of 5.59 and $8.4 million of net debt (47.21 times EBITDA).
What is STRATA Skin Sciences's current ratio?
STRATA Skin Sciences's current ratio was 0.58 at the end of fiscal 2025: current assets were 0.58 times current liabilities.